Literature DB >> 19343753

Breaking the dogma of the metal-coordinating carboxylate group in integrin ligands: introducing hydroxamic acids to the MIDAS to tune potency and selectivity.

Dominik Heckmann1, Burkhardt Laufer, Luciana Marinelli, Vittorio Limongelli, Ettore Novellino, Grit Zahn, Roland Stragies, Horst Kessler.   

Abstract

A suitable substitute: All integrin receptors bind their ligands, which contain an aspartate residue, in the metal-ion- dependent adhesion site (MIDAS). So far all attempts to replace the carboxyl group of aspartate with other, pharmacologically favorable isosteric groups have failed. Now it has been shown that a hydroxamic acid group can replace the carboxyl group; the resulting ligand retains its high binding activity. The picture shows one such ligand in the binding site of alphavbeta3.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19343753     DOI: 10.1002/anie.200900206

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  6 in total

1.  Small Macrocycles As Highly Active Integrin α2β1 Antagonists.

Authors:  Nis Halland; Horst Blum; Christian Buning; Markus Kohlmann; Andreas Lindenschmidt
Journal:  ACS Med Chem Lett       Date:  2014-01-10       Impact factor: 4.345

2.  A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins.

Authors:  Tobias G Kapp; Florian Rechenmacher; Stefanie Neubauer; Oleg V Maltsev; Elisabetta A Cavalcanti-Adam; Revital Zarka; Ute Reuning; Johannes Notni; Hans-Jürgen Wester; Carlos Mas-Moruno; Joachim Spatz; Benjamin Geiger; Horst Kessler
Journal:  Sci Rep       Date:  2017-01-11       Impact factor: 4.379

3.  Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases.

Authors:  Carmen Festa; Simona De Marino; Adriana Carino; Valentina Sepe; Silvia Marchianò; Sabrina Cipriani; Francesco S Di Leva; Vittorio Limongelli; Maria C Monti; Angela Capolupo; Eleonora Distrutti; Stefano Fiorucci; Angela Zampella
Journal:  Front Pharmacol       Date:  2017-03-30       Impact factor: 5.810

Review 4.  It's Time to Shift the Paradigm: Translation and Clinical Application of Non-αvβ3 Integrin Targeting Radiopharmaceuticals.

Authors:  Susanne Kossatz; Ambros Johannes Beer; Johannes Notni
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

5.  Identification of a Common Pharmacophore for Binding to MMP2 and RGD Integrin: Towards a Multitarget Approach to Inhibit Cancer Angiogenesis and Metastasis.

Authors:  Lorenzo Baldini; Elena Lenci; Francesca Bianchini; Andrea Trabocchi
Journal:  Molecules       Date:  2022-02-12       Impact factor: 4.411

6.  Synthesis and Evaluation of a Non-Peptide Small-Molecule Drug Conjugate Targeting Integrin αVβ3.

Authors:  Jannik Paulus; Norbert Sewald
Journal:  Front Chem       Date:  2022-04-11       Impact factor: 5.545

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.